全文获取类型
收费全文 | 982篇 |
免费 | 89篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 57篇 |
妇产科学 | 8篇 |
基础医学 | 87篇 |
口腔科学 | 29篇 |
临床医学 | 168篇 |
内科学 | 212篇 |
皮肤病学 | 13篇 |
神经病学 | 27篇 |
特种医学 | 241篇 |
外科学 | 48篇 |
综合类 | 23篇 |
预防医学 | 85篇 |
眼科学 | 7篇 |
药学 | 35篇 |
中国医学 | 5篇 |
肿瘤学 | 30篇 |
出版年
2024年 | 3篇 |
2023年 | 9篇 |
2022年 | 2篇 |
2021年 | 10篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 25篇 |
2017年 | 14篇 |
2016年 | 19篇 |
2015年 | 23篇 |
2014年 | 29篇 |
2013年 | 27篇 |
2012年 | 21篇 |
2011年 | 23篇 |
2010年 | 39篇 |
2009年 | 54篇 |
2008年 | 36篇 |
2007年 | 11篇 |
2006年 | 16篇 |
2005年 | 8篇 |
2004年 | 10篇 |
2003年 | 19篇 |
2002年 | 16篇 |
2001年 | 21篇 |
2000年 | 12篇 |
1999年 | 14篇 |
1998年 | 49篇 |
1997年 | 54篇 |
1996年 | 64篇 |
1995年 | 48篇 |
1994年 | 43篇 |
1993年 | 47篇 |
1992年 | 15篇 |
1991年 | 7篇 |
1990年 | 14篇 |
1989年 | 34篇 |
1988年 | 30篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 23篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1975年 | 13篇 |
排序方式: 共有1078条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
A multivariate analysis of mortality and hospital admissions with high-flux dialysis. 总被引:8,自引:0,他引:8
J C Hornberger M Chernew J Petersen A M Garber 《Journal of the American Society of Nephrology : JASN》1992,3(6):1227-1237
The use of high-flux dialysis in clinical practice increased rapidly despite an absence of reports on the clinical effectiveness of the technique. Mortality and hospital admission rates of patients treated with high-flux dialysis were evaluated and compared with those of patients treated with conventional dialysis in a hospital-based renal dialysis unit in northern California. By use of a retrospective, cross-over design, 253 patients enrolled in the dialysis unit from January 1987 to January 1991 were studied. During this period, 107 patients were treated with high-flux dialysis for at least 1 month, and all but 17 of them had received conventional dialysis before switching to high-flux dialysis. The remaining 146 patients were treated with only conventional dialysis. Of the 80 patients who died during the study period, 69 were receiving conventional dialysis and 11 were receiving high-flux dialysis. The multivariate analyses, adjusted for age, gender, ethnic background, type of renal failure, comorbid conditions, and duration of ESRD, showed that annual mortality was substantially less for patients treated with high-flux dialysis compared with that for patients treated with conventional dialysis (7 versus 20%; P < 0.001). The difference in the rate of hospital admissions was not statistically significant. In this nonexperimental study, methods were applied to control for selectivity bias and other factors that might confound the apparent treatment effect. The findings suggest that the potential benefits of high-flux dialysis are sufficient to justify further confirmation in a randomized, controlled trial. 相似文献
10.
Does altered biomechanics cause marrow edema? 总被引:21,自引:0,他引:21